Literature DB >> 22681390

Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer.

Yellela S R Krishnaiah1, Mansoor A Khan.   

Abstract

Colorectal cancer (CRC) is the third most common cause of cancer-related death in both men and women. Often, surgical intervention remains the choice in treating CRC. Traditional dosage forms used for treating CRC deliver drug to wanted as well as unwanted sites of drug action resulting in several adverse side effects. Targeted oral drug delivery systems are being investigated to target and deliver chemotherapeutic and chemopreventive agents directly to colon and rectum. Site-specific delivery of a drug to colon increases its concentration at the target site, and thus requires a lower dose with reduced incidence of side effects. The major obstacle to be overcome for successful targeting of drug to colon through oral route is that drug absorption/degradation must be avoided in stomach and small intestine before the dosage form reaches colon. The review includes discussion of physiological factors that must be considered when targeting drugs directly to colorectal region, an outline on drugs used for treatment and prevention of CRC, and a brief description of various types of colon-targeted oral drug delivery systems. The focus is on the assessment of various formulation approaches being investigated for oral colon-specific delivery of drugs used in the treatment and prevention of CRC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22681390     DOI: 10.3109/10837450.2012.696268

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  8 in total

1.  LncRNA, a novel target biomolecule, is involved in the progression of colorectal cancer.

Authors:  Weihong Sun; Shaoshao Ren; Ran Li; Qingshan Zhang; Haiping Song
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

2.  Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway.

Authors:  Xin Xie; Yu Zhao; Chun-Yan Ma; Xiao-Ming Xu; Yan-Qiu Zhang; Chen-Guang Wang; Jing Jin; Xin Shen; Jin-Lai Gao; Na Li; Zhi-Jie Sun; De-Li Dong
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

Review 3.  Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept.

Authors:  Guido Giordano; Antonio Febbraro; Michele Venditti; Serena Campidoglio; Nunzio Olivieri; Katia Raieta; Pietro Parcesepe; Giusy Carmen Imbriani; Andrea Remo; Massimo Pancione
Journal:  Gastroenterol Res Pract       Date:  2014-07-21       Impact factor: 2.260

4.  Cyclodextrin complexes of reduced bromonoscapine in guar gum microspheres enhance colonic drug delivery.

Authors:  Jitender Madan; Sushma R Gundala; Bharat Baruah; Mulpuri Nagaraju; Clayton Yates; Timothy Turner; Vijay Rangari; Donald Hamelberg; Michelle D Reid; Ritu Aneja
Journal:  Mol Pharm       Date:  2014-11-18       Impact factor: 4.939

5.  De-Esterified Tragacanth Microspheres Loaded into Eudragit S-100 Coated Capsules for Colon-Targeted Delivery.

Authors:  Ehsan Ahmadi; Komail Sadrjavadi; Ghobad Mohammadi; Ali Fattahi
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

6.  Colon targeted beads loaded with pterostilbene: Formulation, optimization, characterization and in vivo evaluation.

Authors:  Mudassir Ansari; Bhakti Sadarani; Anuradha Majumdar
Journal:  Saudi Pharm J       Date:  2018-07-20       Impact factor: 4.330

7.  Development of Functionalized Carbon Nano-Onions Reinforced Zein Protein Hydrogel Interfaces for Controlled Drug Release.

Authors:  Narsimha Mamidi; Aldo González-Ortiz; Irasema Lopez Romo; Enrique V Barrera
Journal:  Pharmaceutics       Date:  2019-11-20       Impact factor: 6.321

Review 8.  Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease.

Authors:  Muhammad Bilal; Leonardo Vieira Nunes; Marco Thúlio Saviatto Duarte; Luiz Fernando Romanholo Ferreira; Renato Nery Soriano; Hafiz M N Iqbal
Journal:  Mar Drugs       Date:  2021-03-30       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.